Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK plus chemotherapy in advanced solid tumors
NCT04214717Unknown
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Randomised, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in solid tumor (2 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Disease Control Rate at 1 year. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04214717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214717.